| Autor: |
Wang F; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Li S; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Cheng KW; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Rosencrans WM; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA., Chou TF; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.; Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, CA 91125, USA. |
| Abstrakt: |
The diverse modes of action of small molecule inhibitors provide versatile tools to investigate basic biology and develop therapeutics. However, it remains a challenging task to evaluate their exact mechanisms of action. We identified two classes of inhibitors for the p97 ATPase: ATP competitive and allosteric. We showed that the allosteric p97 inhibitor, UPCDC-30245, does not affect two well-known cellular functions of p97, endoplasmic-reticulum-associated protein degradation and the unfolded protein response pathway; instead, it strongly increases the lipidated form of microtubule-associated proteins 1A/1B light chain 3B (LC3-II), suggesting an alteration of autophagic pathways. To evaluate the molecular mechanism, we performed proteomic analysis of UPCDC-30245 treated cells. Our results revealed that UPCDC-30245 blocks endo-lysosomal degradation by inhibiting the formation of early endosome and reducing the acidity of the lysosome, an effect not observed with the potent p97 inhibitor CB-5083. This unique effect allows us to demonstrate UPCDC-30245 exhibits antiviral effects against coronavirus by blocking viral entry. |
